AN69ST Verse PS in CBP in Septic Children

NCT ID: NCT05692011

Last Updated: 2025-02-20

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 80 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-10-01
• Study Completion Date: 2025-12-31

Brief Summary

In septic shock, dysregulated host responses to pathogens lead to cytokine storms that damage host tissues and organs, further contributing to the development of organ dysfunction and increased mortality. For sepsis, blood purification can remove inflammatory factors in sepsis by filtration or adsorption, so as to achieve the purpose of reducing inflammatory mediators in the body. However, there are few prospective randomized controlled studies in children. Therefore, this study intends to compare the efficacy and prognosis of different membrane on children with sepsis through a perspective cohort study, so as to provide a corresponding basis for the treatment of children with sepsis blood purification.

Detailed Description

Sepsis is a life-threatening organ dysfunction resulting from a dysregulated host response to infection. In septic shock, dysregulated host responses to pathogens lead to cytokine storms that damage host tissues and organs, further contributing to the development of organ dysfunction and increased mortality.

Blood purification therapy is gradually developed on the basis of renal replacement therapy, and now it is more and more widely used in the field of critical care in children. CVVH can reduce the level of inflammation in the body in different membranes, but the results of reducing inflammatory factors are different, and the outcomes of patients are also different.

Blood purification treatment can reduce inflammatory mediators in sepsis, but there are few prospective randomized controlled studies in children. Therefore, this study intends to compare the efficacy and prognosis of different blood purification membrane in children with sepsis through a perspective cohort study. Provide the corresponding basis for blood purification treatment of the disease.

Conditions

Sepsis

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

blood purification(AN69ST)

blood purification(AN69ST)

Intervention Type: DEVICE

After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with AN69ST membrane, 24 hours per day, for 3 consecutive days

blood purification(PS)

blood purification(PS)

Intervention Type: DEVICE

After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with PS membrane, 24 hours per day, for 3 consecutive days

Interventions

blood purification(PS)

After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with PS membrane, 24 hours per day, for 3 consecutive days

Intervention Type: DEVICE

blood purification(AN69ST)

After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with AN69ST membrane, 24 hours per day, for 3 consecutive days

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Meet the 2005 diagnostic criteria for sepsis
• Age 29 days - 18 years old
• Sepsis-induced dysfunction of more than one organ or abnormal tissue perfusion, or septic shock
• Diagnosis < 48 hours

Exclusion Criteria

• Inability to obtain an informed consent from the subject, family member or an authorized surrogate
• Subject has end-stage renal disease and requires chronic dialysis
• There is clinical support for non-septic shock
• Subject has had chest compressions as part of cardiopulmonary resuscitation this hospitalization without immediate return to communicative state
• Subject has uncontrolled hemorrhage
• Subject has immunodeficiency diseases
• Subject has received chemoradiotherapy or immunosuppressive therapy in the 14 days before enrollment
• HIV infection in association with a last known or suspected CD4 count of <50/mm3
• Subject has sustained extensive third-degree burns within the past 7 days
• Subject has known sensitivity or allergy to heparin or has a history of heparin associated thrombocytopenia
• Subject is currently enrolled in an investigational drug or device trial
• Subject has been previously enrolled in the current trial
• Any other condition, that in the opinion of the investigator, would preclude the subject from being a suitable candidate for enrollment, such as end stage chronic illness with no reasonable expectation of survival to hospital discharge
• Known hypersensitivity to hemofilter
• Subject has received organ transplantation
• Subject is expected to die within 24 hours

• Minimum Eligible Age: 29 Days
• Maximum Eligible Age: 28 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

West China Second University Hospital

OTHER

Sponsor Role: collaborator

Children's Hospital of Chongqing Medical University

OTHER

Sponsor Role: collaborator

First Affiliated Hospital of Xinjiang Medical University

OTHER

Sponsor Role: collaborator

Shandong Provincial Hospital

OTHER_GOV

Sponsor Role: collaborator

Children's Hospital of Soochow University

OTHER

Sponsor Role: collaborator

Southern Medical University, China

OTHER

Sponsor Role: collaborator

Children's Hospital of Fudan University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Children's Hospital Of Soochow University

Suzhou, , China

Countries

China

Central Contacts

Jiayun Ying

Role: CONTACT

jiayundoctor@163.com

18817583962

Guoping Lu

Role: CONTACT

13788904150@163.com

13788904150

Facility Contacts

Saihu Huang

Role: primary

Other Identifiers

fdpicu-28

Identifier Type: -

Identifier Source: org_study_id